Table 1.
Baseline demographics of patients with CHC prior to anti-HCV therapy.
| Total (n = 450) | SVR (+) (n = 372) | SVR (−) (n = 78) | p values Obtained Using Student’s t-Test or the Chi-Squared Test | |
|---|---|---|---|---|
| Male, n (%) # | 256 (56.8) | 212 (56.9) | 44 (56.4) | 0.394 |
| Age (years) | 54.01 ± 11.51 | 53.68 ± 11.60 | 55.66 ± 10.92 | 0.160 |
| BMI | 24.99 ± 3.73 | 24.84 ± 3.63 | 25.72 ± 4.09 | 0.057 |
| HCV RNA (Log IU/mL) | 5.95 ± 1.14 | 5.85 ± 1.18 | 6.45 ± 0.74 | <0.001 * |
| HCV genotype, G1, n (%) | 234 (52) | 177 (47.5) | 57 (73) | 0.003 * |
| ALT (U/L) | 94.28 ± 84.95 | 97.18 ± 88.37 | 79.80 ± 63.85 | 0.116 |
| TC (mg/dL) | 171.76 ± 32.22 | 171.53 ± 32.75 | 172.91 ± 29.62 | 0.735 |
| TGs (mg/dL) | 103.25 ± 50.15 | 101.21 ± 46.21 | 113.57 ± 66.05 | 0.123 |
| Platelet count (103 cells/mm) | 176.89 ± 64.54 | 181.27 ± 57.86 | 156.89 ± 58.72 | 0.001 * |
| HOMA-IR | 3.14 ± 4.91 | 2.89 ± 4.70 | 4.42 ± 5.73 | 0.043 * |
| Hepatic steatosis, n (%) # | 220 (48.8) | 186 (50) | 34 (43.5) | 0.373 |
| Liver cirrhosis, n (%) # | 117 (26) | 83 (22.3) | 34 (43.5) | 0.001 * |
| APRI | 1.51 ± 1.66 | 1.47 ± 1.63 | 1.74 ± 1.83 | 0.210 |
| Leptin (ng/mL) | 9.82 ± 10.1 | 9.33 ± 9.05 | 12.2 ± 14.1 | 0.267 |
| Adiponectin (μg/mL) | 9.74 ± 7.15 | 10.1 ± 7.48 | 8.04 ± 5.22 | 0.097 |
| Leptin (ng/mL)/adiponectin (μg/mL) ratio | 2.14 ± 3.79 | 2.06 ± 4.10 | 2.45 ± 3.00 | 0.603 |
| PAI-1 (ng/mL) | 6.73 ± 3.11 | 6.76 ± 2.98 | 6.56 ± 3.69 | 0.658 |
| rs12979860 (CC) n (%) # | 379 (84.2) | 328 (88.1) | 88 (65.3) | 0.013 * |
SVR: sustained virological response; #: chi-squared test; * p < 0.05; BMI: body mass index; G: genotype; Log: logarithmic; ALT: alanine aminotransferase; TC: total cholesterol; TGs: triglycerides; HOMA-IR: homeostasis model assessment-estimated insulin resistance; APRI: aspartate aminotransferase to platelet ratio index; PAI-1: plasminogen activator inhibitor-1.